pipette
ESEspañol

Temporal control of mitochondrial mutagenesis reveals the fate of mtDNA mutations with age

S. J. Shemtov, E. Hwang, C. S. Chung, H. Anson, L. Carrillo, S. Lee, I. Vorobyova, J. Wan, S. R. Kennedy, A. R. Vandiver, B. M. Verheijen, W. Cohn, B. A. Benayoun, M. A. Thorwald, P. Cohen, J. Wanagat, J.-F. Gout, M. Vermulst

PreprintBold claims, read critically

In the authors' words

Mutations in the mitochondrial genome (mtDNA) play a critical role in the aging process and a wide variety of age-related diseases. However, it remains unclear when the mutations that drive physiological decline arise. To answer this question, we generated a new mouse model in which mitochondrial mutagenesis can be confined to a defined window of time. Surprisingly, we found that mutations that arise during the first two months of life are sufficient to drive a wide variety of age-related pathologies, and that the severity of this pathology is broadly regulated by distinct, tissue-specific selective pressures that control the fate of mtDNA mutations with age. Further, we found that selection against deleterious variants can be modulated by manipulation of mitochondrial fusion in vitro and in vivo. These observations raise the possibility that in some tissues, the pace of aging is pre-determined by events that occur early in life and that interventions targeting mitochondrial fusion may be able to slow down or reverse the expansion of these pathogenic variants. These results carry far-reaching implications for strategies aimed at preventing or delaying age-related decline.

Main resultThe abstract does not state a limitation.

Appeared: Monday, September 28. bioRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.09.24.754271